The legal landscape of marijuana in the United States is complex, with significant disparities between federal law and state regulations. At the federal level, marijuana is classified as a Schedule I substance according to the Drug Enforcement Administration (DEA), indicating a high potential for abuse and no accepted medical use. However, as of March 1, 2023, 37 states, the District of Columbia (DC), Puerto Rico, Guam, and the U.S. Virgin Islands have diverged from this stance, adopting laws that permit medicinal use of marijuana.
California, a trailblazer in this arena, legalized medicinal cannabis in 1996 through the Compassionate Use Act. Today, cannabis is legal in California for both medicinal and recreational use, with detailed regulations ensuring business operations are safe, products are free from contaminants, and properly labeled to inform consumers. The Department of Cannabis Control provides comprehensive guidance on what is permissible within the state.
Connecticut has also joined the ranks of states legalizing cannabis for adult use. Residents over 21 can possess and consume marijuana legally, with the state government providing a wealth of information on the new laws. In New Jersey, a distinction is made between regulated “cannabis” and unregulated “marijuana,” reflecting the state’s legal framework for the plant’s use.
While states continue to reform their cannabis laws, the federal government has also shown signs of shifting perspectives. A recent statement from President Biden on marijuana reform indicates an evolving federal stance, although the core limitations on trafficking, marketing, and underage sales remain intact.
Understanding the disparities between federal and state regulations is critical, as they can have profound implications for individuals and businesses alike. The Congressional Research Service provides analysis of the expanding policy gap, while the Centers for Disease Control and Prevention (CDC) offers insights into the health effects and chemical properties of marijuana. Moreover, the Food and Drug Administration (FDA) continues to regulate cannabis and cannabis-derived products, including CBD, ensuring safety and efficacy in the market.